Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

The appraisal committee has prepared final draft guidance (FDG) on vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over, and submitted it to NICE.

The FDG has been sent to consultees for this appraisal who have 5 working days to advise if they wish to appeal against it and/or notify us of any factual errors. If an intent to appeal is submitted the consultees will have an additional 10 working days to submit their appeal. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.

Please note that the intentions to appeal for this appraisal must be submitted by 5pm, Tuesday 15 July 2025.